The World Health Organization published new comprehensive guidelines recommending GLP-1 receptor agonists for adults with obesity, expanding previous guidance to include drugs like tirzepatide, semaglutide, and liraglutide alongside behavioral interventions.Tedros Adhanom Ghebreyesus called obesity a global health crisis and recognized that most people will need lifelong therapy combining medication and behavioral support due to frequent weight regain.Despite rising use and benefits for weight and health, access to GLP-1 drugs remains limited, and fewer than 10% of those needing therapy are projected to have access globally by 2030.